Literature DB >> 26654198

Patient-reported outcome measures for adult chronic rhinosinusitis: A systematic review and quality assessment.

Luke Rudmik1, Claire Hopkins2, Anju Peters3, Timothy L Smith4, Rodney J Schlosser5, Zachary M Soler5.   

Abstract

BACKGROUND: With a focus on patient-centered care, there is increasing policy interest in patient-reported outcome measures (PROMs) to inform improvements in health care delivery. Given the importance of understanding patient-reported outcomes during the management of chronic rhinosinusitis (CRS), PROMs will play an essential role in informing and tailoring the right intervention to the right patient.
OBJECTIVE: The objective of this systematic review was to identify and assess the quality of PROMs being used for adults with CRS.
METHODS: A systematic review of Ovid MEDLINE (R) (1947-May 2015), Embase, and the Cochrane databases was performed using the following key terms: ["chronic" AND "*sinusitis"] AND [PROM OR patient reported outcome measure* OR quality of life OR questionnaire OR survey OR valid* OR develop*]. An unlimited truncation strategy (placement of *) was used to capture all variations of terms used. The quality of each PROM was assessed and reported using standardized criteria from the COnsensus-based Standards for the selection of health status Measurement INstruments checklist.
RESULTS: A total of 15 PROMs validated for use in adult patients with CRS were identified. Fourteen instruments were specific to adults with CRS, and one was a generic quality-of-life instrument (EuroQol five-dimensional questionnaire [EQ-5D]). There was significant variation in the quality of development and reporting of psychometric properties. Overall, the highest quality validated PROMs for adults with CRS were (1) the 22-item Sinonasal Outcome Test (19 points), (2) the Questionnaire of Olfactory Disorders (14 points), (3) the Sinusitis Control Test (14 points), and (4) the EQ-5D (13 points). Most of the PROMs were developed for research purposes such as determining changes in health-related quality of life or symptoms after an intervention as opposed to improving clinical decision making.
CONCLUSIONS: Based on quality assessment, the 22-item Sinonasal Outcome Test, the Questionnaire of Olfactory Disorders, and the Sinusitis Control Test provided the highest quality CRS-specific PROMs, whereas the EQ-5D provided the highest quality generic quality-of-life instrument. Future CRS PROMs will need to incorporate clinical domains that assess common comorbid diseases along with patient values and preferences to improve clinical decision making.
Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic rhinosinusitis; evidence-based medicine; patient-reported outcome measure; quality of life; sinusitis; systematic review

Mesh:

Year:  2015        PMID: 26654198     DOI: 10.1016/j.jaci.2015.10.012

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  37 in total

Review 1.  Patient and Public Outreach Initiatives in Chronic Rhinosinusitis from the Canadian Sinusitis Working Group: Support for Affected Patients and Extending an Understanding of CRS to the General Public.

Authors:  Smriti Nayan; Shaun Kilty; Helen Buckie Lloyd; Martin Desrosiers
Journal:  Curr Allergy Asthma Rep       Date:  2017-07       Impact factor: 4.806

2.  Symptom importance, patient expectations, and satisfaction in chronic rhinosinusitis.

Authors:  Jose L Mattos; Luke Rudmik; Rodney J Schlosser; Timothy L Smith; Jess C Mace; Jeremiah Alt; Zachary M Soler
Journal:  Int Forum Allergy Rhinol       Date:  2019-02-12       Impact factor: 3.858

Review 3.  Sleep disruption in chronic rhinosinusitis.

Authors:  Mahboobeh Mahdavinia; Robert P Schleimer; Ali Keshavarzian
Journal:  Expert Rev Anti Infect Ther       Date:  2017-02-17       Impact factor: 5.091

4.  Long-term outcomes of endoscopic sinus surgery in the management of adult chronic rhinosinusitis.

Authors:  Timothy L Smith; Rodney J Schlosser; Jess C Mace; Jeremiah A Alt; Daniel M Beswick; Adam S DeConde; Kara Y Detwiller; Jose L Mattos; Zachary M Soler
Journal:  Int Forum Allergy Rhinol       Date:  2019-06-17       Impact factor: 3.858

Review 5.  Sino-Nasal outcome test-22 outcomes after sinus surgery: A systematic review and meta-analysis.

Authors:  Zachary M Soler; Rabun Jones; Phong Le; Luke Rudmik; Jose L Mattos; Shaun A Nguyen; Rodney J Schlosser
Journal:  Laryngoscope       Date:  2017-11-22       Impact factor: 3.325

Review 6.  Systematic Reviews and Meta-analysis in Rhinosinusitis: a Critical Review of the Reviews.

Authors:  Abigail Walker; Claire Hopkins
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-16       Impact factor: 4.806

7.  What drives productivity loss in chronic rhinosinusitis? A SNOT-22 subdomain analysis.

Authors:  Naweed I Chowdhury; Jess C Mace; Timothy L Smith; Luke Rudmik
Journal:  Laryngoscope       Date:  2017-06-10       Impact factor: 3.325

8.  Evaluating metrics of responsiveness using patient-reported outcome measures in chronic rhinosinusitis.

Authors:  Alcina K Lidder; Kara Y Detwiller; Caroline P E Price; Robert C Kern; David B Conley; Stephanie Shintani-Smith; Kevin C Welch; Rakesh K Chandra; Anju T Peters; Leslie C Grammer; Li-Xing Man; Robert P Schleimer; Bruce K Tan
Journal:  Int Forum Allergy Rhinol       Date:  2016-11-07       Impact factor: 3.858

9.  A brief version of the questionnaire of olfactory disorders in patients with chronic rhinosinusitis.

Authors:  Jose L Mattos; Campbell Edwards; Rodney J Schlosser; Madison Hyer; Jess C Mace; Timothy L Smith; Zachary M Soler
Journal:  Int Forum Allergy Rhinol       Date:  2019-08-20       Impact factor: 3.858

10.  Comparing surgeon outcomes in endoscopic sinus surgery for chronic rhinosinusitis.

Authors:  Timothy L Smith; Jess C Mace; Luke Rudmik; Rodney J Schlosser; Peter H Hwang; Jeremiah A Alt; Zachary M Soler
Journal:  Laryngoscope       Date:  2016-06-14       Impact factor: 3.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.